Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bifonazole once daily · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | PLACEBO_COMPARATOR | - |
| Arm 4 | PLACEBO_COMPARATOR | - |
| Arm 5 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Bifonazole spray once daily | DRUG | Application of one dose daily by means of an metered dose |
| Bifonazole spray twice daily | DRUG | Application of two dose daily by means of an metered dose |
| Placebo | DRUG | Application of one dose daily by means of an metered dose |
| Lamisil Once | DRUG | One application of Lamisil Once |
Inclusion Criteria: * Male or female subjects aged between 18 and 70 years * Positive clinical findings of athlete's foot, limited to interdigital spaces, with a total athlete's foot severity score (AFSS) of at least 5 and not exceeding 10 points for the signs and symptoms of athlete's foot, and no...
Bifonazole once daily is an investigational small molecule being studied for the treatment of Tinea Pedis, a fungal infection of the feet. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Bifonazole once daily is an antifungal agent. It is being evaluated for its efficacy and safety in treating Tinea Pedis, a common fungal skin infection. The specific molecular target of this drug has not been disclosed in the available clinical trial information.
Bifonazole once daily is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY on the OTC market.
Bifonazole once daily is in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval. The drug is being studied for the treatment of Tinea Pedis.
Bifonazole once daily has one completed Phase 2 clinical trial, NCT01013909, titled 'Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo'. This randomized, placebo-controlled trial enrolled 220 participants with Tinea Pedis in Germany.
Bifonazole once daily is a formulation of bifonazole, an antifungal medication. The 'once daily' designation indicates the intended dosing frequency. In clinical trials, it is being studied as a spray formulation for the treatment of Tinea Pedis.